Table 1.
Clinical details and outcomes by line of treatment
| Second line | Third line | Fourth line | Fifth line | Sixth line | Seventh line | Eighth line | |
|---|---|---|---|---|---|---|---|
| Patients, n | 12 | 9 | 7 | 5 | 4 | 1 | 1 |
| Male, n | 12/12 | 8/9 | 6/7 | 5/5 | 4/4 | 1/1 | 1/1 |
| Leukocytes (mm−3) | 2 250 | 1 740 | 2 600 | 1 800 | 2 950 | 1 600 | 5 900 |
| Neutrophils (mm−3) | 660 | 1 160 | 1 300 | 740 | 1 350 | 1 072 | 2 000 |
| Hemoglobin (g/dL) | 13.4 | 11.3 | 13.1 | 11.6 | 12.7 | 11.7 | 7.6 |
| Platelets (mm−3) | 72 000 | 89 000 | 56 000 | 100 000 | 97 000 | 77 000 | 21 000 |
| Splenomegaly | 33% | 33% | 0 | 20% | 0 | 0 | 0 |
| Last therapy before rituximab | Cladribine (100%) | Cladribine (89%) Rituximab (11%) |
Cladribine (86%) Interferon (14%) |
Cladribine (60%) Interferon (40%) |
Rituximab (50%) Cladribine (25%) Pentostatin (25%) |
Rituximab (100%) | Cladribine (100%) |
| Early interruption of rituximab, n | 1 (death) | None | 1 (cytopenia) | None | 1 (cytopenia) 1 (infusion reaction) |
None | None |
| Next therapy after rituximab | Cladribine (50%) Rituximab (25%) Vemurafenib (25%) |
Cladribine (60%) Interferon (20%) Rituximab + vemurafenib (20%) |
Vemurafenib (20%) Pentostatin (40%) Chlorambucil (20%) Cladribine (20%) |
Rituximab (50%) Cladribine (25%) Interferon (25%) |
Interferon (50%) Cladribine (25%) Rituximab (25%) |
None | None |
| Overall response | 75.0% | 88.9% | 57.1% | 80.0% | 50.0% | 100% | 0 |
| Complete response | 41.7% | 33.3% | 0 | 20.0% | 25.0% | 100% | 0 |
| Further treatment | 36.4% | 55.6% | 71.4% | 80.0% | 100% | 0 | 0∗ |
| Month to relapse, range | 2.6-24.9 | 2.5-109.0 | 1.2-28.8 | 10.0-37.5 | 1.5-193.7 | N/A | N/A∗ |
N/A, not assessable.
∗
Patient deceased in the post-rituximab follow-up.